Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Carrie Parrish Nyekan

Nurse Practitioner, Family Bowling Green, KY Nurse Practitioner

NPI 1104107473 CMS profile 1396053

201 Park St, Bowling Green, KY 42101

Open in the dashboard

General payments

$55,422

1,103 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carrie Parrish Nyekan of Bowling Green, KY is reported in the CMS Open Payments database as having received $55,422 across 1,103 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,664 237
2024 General $3,803 239
2023 General $18,152 205
2022 General $27,129 235
2021 General $2,675 187

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carrie Parrish Nyekan
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Carrie Parrish Nyekan were reported at $3,664. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Carrie Parrish Nyekan Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,675 $124 $35–$379 $132
2022 $27,129 $141 $44–$430 $149
2023 $18,152 $154 $49–$476 $160
2024 $3,803 $165 $51–$504 $164
2025 $3,664 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $36,956 126 payments
  2. Mannkind Corporation $5,146 101 payments
  3. Novo Nordisk Inc $1,858 149 payments
  4. Amgen Inc. $1,399 103 payments
  5. Lilly USA, LLC $1,388 84 payments
  6. Insulet Corporation $1,379 80 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $1,186 77 payments
  8. Corcept Therapeutics $810 48 payments
  9. Novartis Pharmaceuticals Corporation $774 61 payments
  10. Medtronic, Inc. $690 50 payments
  11. Other $3,837 224 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $29,976 15 payments
  2. Food and Beverage $16,437 1,060 payments
  3. Travel and Lodging $7,936 19 payments
  4. Consulting Fee $952 5 payments
  5. Education $121 4 payments
Products named General payments · program years 2021–2025
  1. Kerendia $36,152 125 payments
  2. AFREZZA $5,146 101 payments
  3. Omnipod $1,379 80 payments
  4. Korlym $810 48 payments
  5. Repatha $789 50 payments
  6. LEQVIO $774 61 payments
  7. Ozempic $754 52 payments
  8. RYBELSUS $723 50 payments
  9. MOUNJARO $684 43 payments
  10. JARDIANCE $622 41 payments
  11. Other $8,077 551 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 90 drugs

Part D claims

8,823

Median for Nurse Practitioner: 389

Drug cost

$4,592,330

Median for Nurse Practitioner: $21,885

Branded share of claims

66.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 644 $813,687
Mounjaro Tirzepatide Brand 418 $491,589
Farxiga Dapagliflozin Propanediol Brand 384 $380,416
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 191 $324,363
Tresiba Flextouch U-200 Insulin Degludec Brand 263 $321,887
Humulin R U-500 Kwikpen Insulin Regular, Human Brand 138 $317,484
Jardiance Empagliflozin Brand 271 $259,005
Trulicity Dulaglutide Brand 145 $235,079
Kerendia Finerenone Brand 164 $148,410
Tresiba Flextouch U-100 Insulin Degludec Brand 148 $125,480

The 10 drugs with the highest cost, of 90 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$150,605

Of which drugs: $74,515

Medicare patients

419

Average age 70

Services billed

11,491

275 women, 144 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 74%
Arthritis 43%
Chronic kidney disease 38%
Ischemic heart disease 34%
Depression 24%
Heart failure 22%
COPD 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 16 1,620 $33,124

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AFREZZA
$367 — —
Kerendia
$318 164 —
LEQVIO
$294 — —
JARDIANCE
$266 271 —
Repatha
$193 88 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

1,103 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record